InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,346.00
(
0.42%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
86.07
(
0.76%
)
Bitcoin
61,344.13
(
-0.43%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

growacet

Send PM Follow Ignore
Followers 29
Posts 3997
Boards Moderated 0
Alias Born 10/16/2003

growacet

Re: None

Tuesday, 08/28/2018 6:52:43 AM

Tuesday, August 28, 2018 6:52:43 AM

Post# of 252412
Who's heard of Epigenetics and BET Inhibition?

Newer area of the biotech space and one early mover is way out in front, Resverlogix with a drug named Apabetalone nearing the end of a Phase III event based trial for patients with Diabetes Mellitus as well as subsets of patients on dialysis (Chronic Kidney Disease) and reduced Cognitive function, (Alzheimer's).

This has blockbuster written all over it, but very the company is very quiet. No promoters or IR consultant types hyping it.

I guess they figure they don't need it. Here's a SA blog post I did.

https://seekingalpha.com/instablog/15663412-joe_retail/5205099-apabetalone-billion-dollar-blockbuster-making

If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up